Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Elranatamab by Pfizer for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Elranatamab is under clinical development by Pfizer and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...